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Introduction 
Positron emission tomography/computed tomography (PET/CT) with18F-flourodeoxyglucose 
(FDG) has a clear role in oncological applications with the fused images1,2 providing 
improved detectability and lesion localisation accuracy.3 Furthermore, the use of diagnostic 
quality CT with PET can offer advantages over standalone CT for accurate staging of 
disease due to a better assessment of nodal and metastatic involvement.4 However, the 
benefits of these examinations need to be balanced against the lifetime attributable risk of 
cancer from a combined PET/CT investigation.5 
Patient dose associated with PET/CT can be very high, and a high proportion of the dose is 
due to the diagnostic quality (DQ) CT examination. Recent technological improvements, 
notably time of flight (TOF),6,7 have been implemented to enable the superior spatial 
resolution of modern PET/CT systems, and along with a strategy of calculating weight based 
injected activity8–10 it has resulted in reduced radiation dose, with a preference to increase 
emission time rather than injected activity for obese patients.6 Early reports of radiation dose 
in PET/CT, combining 18F-FDG with DQ CT could produce effective dose in the range of 24-
46 mSv.5,11,12 However, a more recent Korean study reports an average radiation dose of 
12.2 mSv, based on a mean injected activity of 5.111.19 MBq per Kg and CT scan for 
attenuation correction (AC).10 This is in line with other studies using CT for AC only, where a 
dose of 8.5 mSv has been reported.11 In other words, by not acquiring the DQ images one 
can reduce the dose by up to a factor of 3. Before this is done one needs to assess the loss 
of lesion detection performance associated with not acquiring DQ images. 
The EANM provides guidelines for different CT scanning strategies in PET/CT13 and the 
authors of the current study also recognise that funding and availability of contrast media 
may also dictate protocol, with variations in practice globally. In the UK, typical practice is for 
low-dose CT to be performed on all patients for AC. DQCT would only be required for a 
limited field of view over an area of clinically relevant interest if a standalone DQCT has not 
yet been completed. However, the evaluation of images suitable for CTAC can be difficult, 
with low positive predictive values reported in single photon emission computed 
tomography/computed tomography (SPECT/CT).14 Nodule detection within the thorax has 
high clinical importance since a nodule can represent an early manifestation of lung 
cancer.15 For small nodules, FDG-PET can be associated with false negatives,15 thus giving 
more importance to the CT data for nodule detection. Evaluation of CTAC images remains a 
controversial issue, with variations in reporting practice down to local protocol and 
interpretations of IRMER regulation 7.8; ‘…ensure that a clinical evaluation of the outcome of 
each medical exposure is recorded’.16  
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A previous study17 has assessed nodule detection performance in the CT images acquired  
for AC during SPECT/CT. This observer performance study compared nodule detection in 
the AC images produced by a range of CT acquisition parameters on systems from different 
manufacturers, revealing significant differences in nodule detection between SPECT/CT 
systems for images acquired for AC.17 However, this study did not compare AC and DQ 
images for nodule detection on the same PET/CT system. 
The purpose of our study is to compare the nodule detection performance provided by 
images acquired with diagnostic quality against those acquired with the primary purpose of 
AC. 
 
Method 
Image Acquisition 
AC and DQ images were acquired on a GE Discovery 670 64-slice PET/CT system (General 
Electric Healthcare, Waukesha, WI, USA). CT images of the anthropomorphic chest 
phantom (Lungman N1 Multipurpose Chest Phantom, Kyoto Kagaku Company Ltd, Japan) 
were acquired for five different configurations of nodule position. For each configuration, the 
phantom was loaded with 12 nodules, measuring 5, 8, 10 and 12 mm diameters and 
contrasts -800, -630 and +100 HU. The size, HU and precise anatomical position of all 
nodules were recorded at the time of insertion. There were no duplicate nodules, i.e., 
nodules with same diameters and contrasts, in the same transaxial slice. 
The CT images were acquired per the imaging protocol of our clinical partner, summarised in 
Table 1. AC and DQ images were acquired with automatic tube current modulation (ATCM). 
The CT component of this hybrid system uses a manufacturer termed “noise index” for 
automatic exposure control. The “noise index”, referenced to the standard deviation of CT 
numbers in a water phantom measured on the CT scout (planning image), uses an algorithm 
to maintain levels of image noise as attenuation varies between projections.18–20 The 
minimum and maximum tube current (mA) and “noise index” were set for AC and DQ 
acquisitions. Table 1 lists the remaining technical parameters used to acquire the AC and 
DQ images. Scan and reconstruction field of view (FOV) are protocol driven: to provide 
correction of photon attenuation (AC) and for image fusion (DQ). The remaining difference in 
acquisition parameters between AC and DQ images is the reconstructed slice thickness. 
Dose length product (DLP) is reported by the CT scanner as an estimate of dose received; 
computed tomography dose index (CTDI) is not a robust measure of dose for evaluations 
using ATCM.21 
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Acquisition kVp Noise 
Index 
Mean mA 
(min-max) 
Recon. 
Slice 
(mm) 
Pitch Matrix 
Size 
Scan 
FOV 
(mm) 
Recon 
FOV 
(mm) 
Pixel 
Size 
(mm) 
DLP 
(mGy-cm) 
AC 120 40.00 
34.8±4.8 
(30-42) 
2.5 1.375 512x512 700 500 0.98 44.6 
DQ 120 24.24 
228.5±53.2 
(143-292) 
1.25 1.375 512x512 500 360 0.70 243.3 
Table 1: The parameters used for image acquisition and reconstruction for both diagnostic quality (DQ) CT 
and CT for attenuation correction (AC). Noise index is the standard deviation of pixel values; this determines 
the mean tube current (mA) within a pre‐determined range (max‐min). FOV, field of view; Recon, 
reconstruction.  
 
Observer Performance Study 
A total of 45 normal cases (trans-axial slices with no simulated nodules) and 47 abnormal 
cases (transaxial slices) containing 1-3 simulated nodules (average 1.26 per abnormal case) 
were selected for the observer study from the AC and DQ image data. A case was defined 
as a single transaxial slice. A histogram illustrates the distribution and type of nodules used 
in this study, Figure 1. Image display and recording of interpretations were performed using 
ROCView22 (Bury St Edmunds, UK, www.rocview.net) using a 22” widescreen monitor at 
60Hz (HP L2245wg, 1680x1050, 1.8 megapixels, Hewlett Packard, Palo Alto, CA, USA) 
calibrated using X-Rite i1 and Eye-One Match 3 software (X-Rite, Grand Rapids, MI, USA). 
Observers were instructed to mark the centre of each nodule using a mouse click.  A slider-
bar rating scale (1-10) was used to rate confidence. An acceptance radius (AR), defined as 
the maximum distance, in order to be classified as a lesion localization, between the centre 
of a mark and the centre of the nearest nodule, was used to classify marks as lesion 
localization. This was set at 20-pixels. 
 
Figure 1: A histogram to explain the frequency and type of simulated nodules used in this study. 
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Cases were displayed in a different randomised order for each observer but on a fixed lung 
window (width 1500, level -500) for optimal evaluation of the simulated nodules. The 
observers comprised of 4 radiographers (5-16 years CT experience), 3 radiographers who 
provide diagnostic reports as part of their practice (2-14 years CT experience) and 2 nuclear 
medicine technologists (2-3 years CT experience). The nine observers were informed of the 
approximate 50:50 ratio of normal and abnormal cases and the range and characteristics of 
the nodules. Observers were also provided with a training dataset of ten images to 
familiarise themselves with the appearances of the phantom and nodules, and the procedure 
to mark and rate the nodules under the free-response paradigm using the user interface. 
These training requirements were deemed adequate since there was no need to manipulate 
images, while a phantom removes the influence of case variation. Additionally, the 
requirement for image randomisation and consideration of memory effect precautions, that 
are standard with clinical studies, are unnecessary with this phantom study. 
 
Statistical Analysis 
Since the observer task required the localisation of nodules we desired an analysis method 
that accounts for localisation. The ROC paradigm considers only a single rating for the entire 
case, thus ignoring the location of the nodules. The equally weighted jackknife alternative 
FROC JAFROC (wJAFROC) figure of merit23, which accounts for location information, is the 
weighted empirical probability that a lesion is rated higher than any mark on a normal case. 
In addition to this, the area under the empirical highest rating inferred ROC curve was also 
used as a figure of merit. A random reader fixed case analysis was performed to test for a 
statistical difference in nodule detection performance. Case was regarded as a fixed factor 
because case variability does not apply to when using a single phantom; of course, the 
results are then specific to the phantom used. 
Data were analysed using an R24 package implemented JAFROC analysis, available at 
(https://cran.r-project.org/web/packages/RJafroc/index.html). Two situations were analysed: 
(i) wJAFROC; and (ii) a highest-rating inferred ROC analysis (HR inferred ROC) that was 
derived from FROC data. A difference in nodule detection performance was considered 
statistically significant when the p-value of the overall F-test was less than 0.05, or 
equivalently, the 95% confidence interval for the treatment pairing did not include zero. To 
control the probability of Type I error test alpha was set at 0.05. 
 
Results 
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Nodule detection as measured by either FOM was significantly better on the diagnostic 
quality images. The relevant statistics, P values, treatment difference and FOMs, including 
95% confidence intervals (CI) are summarised in Table 2, which lists the wJAFROC analysis 
and the HR inferred ROC analysis. The FOM differences in Table 2 are negative since AC is 
treated as the first modality in the analysis, and the FOM for AC was smaller than that for 
DQ. We also analysed the data in terms of lesion level detection (sensitivity) using the 
maxLLF (maximum lesion localisation fraction) FOM in Rjafroc. Again, a statistically 
significant difference was found in favour of DQ (F(1,8) = 56.25, p = 0.0001); DQ FOM 
0.857(0.779,0.935), AC FOM 0.751(0.673,0.830). Typical images for DQ and AC are shown 
in Figure 2a & 2b. 
 
Analysis F-Statistic P value FOM Difference 
(95% CI) 
Figure of Merit (95% CI) 
AC DQ 
wJAFROC F(1,8) = 24.18 0.0012 -0.07 (-0.11,-0.04) 0.776 (0.693,0.858) 0.849 (0.789,0.910) 
HR Inferred ROC F(1,8) = 10.13 0.0129 -0.05 (-0.09,-0.01) 0.847 (0.787,0.907) 0.899 (0.862,0.936) 
Table 2: The wJAFROC and highest rating inferred ROC statistics, figures of merit and inter‐treatment 
difference with 95% confidence intervals (CI). Both analyses were sensitive enough to find a statistical 
difference in nodule detection performance, where the P value was less than 0.05 and the 95% CI of the 
treatment difference did not include zero. 
 
 
Figure 2: An example of the images produced with DQ (a) and AC (b). This case shows two nodules labelled 1 
(right simulated lung, 10 mm 100 HU nodule) and 2 (left simulated lung, 8 mm ‐800 HU nodule). 
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The wJAFROC analysis showed a notable increase in statistical significance over the HR 
inferred ROC analysis, where the ROC analysis produced the expected inflation in figure of 
merit with a smaller treatment difference, Table 2. An inflated FOM is evident with the 
inferred ROC analysis since the wJAFROC FOM uses only the correctly localised lesions; 
the occasions where a non-lesion localisation (NL) rating exceeds the lesion localisation (LL) 
rating are not included. The ROC FOM does include these ratings, as it is not sensitive to 
location data; as a result the fraction of cases where a diseased case is rated higher than a 
non-diseased case is increased. A larger difference between DQ and AC is seen with 
wJAFROC as it is measured over a larger range (0 to 1, wAFROC; 0.5 to 1, ROC). 
Despite the lower statistical significance of the HR inferred ROC analysis it is important to 
note that the difference between the two treatments (AC and DQ) was large enough for a 
statistical difference to be observed even with ROC analysis. Observer averaged empirical 
wAFROC plots and the corresponding highest-rating inferred ROC plots for DQ and AC 
images are displayed in Figure 3. 
To analyse the impact of mAs and slice thickness, and thus determine the controlling factor 
on nodule detection, we eliminated the smallest nodules (5 mm) from supplementary 
analyses. We hypothesised that if a statistically significant difference remained between 
CTAC and DQCT then it is more likely that tube charge (mAs) is the controlling factor, rather 
than slice thickness. We again performed wJAFROC and HR inferred ROC analysis, Table 
3. For the sub-evaluation it is necessary to apply a Bonferroni correction to account for 
multiple comparisons. The corrected value of alpha is 0.05/2 (or 0.025). 
 
Supplementary 
Analysis 
F-Statistic P value FOM Difference 
(95% CI) 
Figure of Merit (95% CI) 
AC DQ 
wJAFROC F(1,8) = 8.60 0.0189 -0.04 (-0.07,-0.01) 0.829 (0.760,0.898) 0.868 (0.817,0.918) 
HR Inferred ROC F(1,8) = 4.95 0.0568 -0.03 (-0.06,0.00) 0.890 (0.839,0.941) 0.920 (0.888,0.951) 
Table 3: Results of supplementary analyses with 5 mm nodules removed from the dataset, showing the 
wJAFROC and highest rating inferred ROC statistics, figures of merit and inter‐treatment difference with 95% 
confidence intervals (CI). Only the wJAFROC method was sensitive enough to show a significant difference 
between AC and DQ. 
Even with removal of the 5 mm nodules the  wAFROC analysis shows a significant 
difference between DQ and AC (p-value lower than the Bonferroni corrected value of alpha), 
suggesting that the main contributor to the difference is the large difference in mAs - which 
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implies more noise in the AC images - which would impact on detectability of low contrast 
large nodules. This would suggest that the controlling influence on nodule detection was 
tube charge (mAs) for the nodules and phantom reported in this study, since removal of the 
smaller nodules, most likely to be affected by slice thickness, did not change the overall 
outcome. This supplementary analysis adds weight to the additional value of location based 
analysis methods in observer studies, where the HR inferred ROC analysis was not sensitive 
to this result. 
Analysis of nodule detection rates between AC and DQ showed that differences existed for 
most nodule types of size and contrast. However, the detection difference was largest for 
5mm nodules with 93 successful localisations on DQ images and 64 successful localisations 
on AC images. 
 
Figure 3: The empirical reader‐averaged wAFROC plot and the corresponding highest‐rating inferred ROC 
plot. 
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Discussion 
This study found nodule detection to be significantly poorer on images acquired for AC 
compared to DQ. Based on these results we do not advocate acquiring only AC images if 
nodule detection in the size range quoted in this study is required. The limited usefulness of 
the AC images for nodule detection may have implications for PET/CT protocols that use AC 
only, if the focus of the examination is pulmonary nodules.  
A supplementary analysis, excluding the smallest nodule size (5 mm), still generated a 
statistically significant result. This is suggestive of tube charge (mAs) being the controlling 
factor in this work, rather than slice thickness. In this study the average mAs, as controlled 
by ATCM, for the DQ images was much higher at 228.5±53.2 (range 143-292) compared to 
34.8±4.8 (range 30-42) for the AC images. This effect of mAs seems to be confirmed by 
other recent work.25 However, the potential impact of spatial resolution should not be 
ignored, since smaller slice thickness can result in higher nodule contrast due to decreased 
partial volume effects. Pixel size will also be reduced in AC image; this loss of resolution can 
be unavoidable since a larger field of view is required to minimise truncation artefacts.26 
Several authors12,27,28 have considered dose optimisation in PET/CT using subjective 
evaluations to compare image quality of AC acquisitions. None of the previous works 
evaluating radiation dose in PET/CT reported observer performance studies. The limitations 
of objective and subjective evaluations are often overlooked in evaluations of technology. 
However, these studies suggest agreement with the current study, finding low-dose CT not 
to be equivalent to DQ CT. A clinical evaluation of the AC image in SPECT/CT has come to 
our attention during the writing of this work. Coward et al14 reviewed the AC images in 3485 
patients attending for myocardial perfusion imaging; they found a positive predictive value of 
only 12% for incidental findings revealed in the AC image, suggesting that routine reporting 
of these images was not beneficial. This would appear to confirm the findings of our study. 
It is important to note that lesion detection in clinical PET/CT is not reliant only on CT 
imaging. The metabolism of a lesion is also important in PET/CT; a small lesion that is 
metabolically active is likely to be seen on PET even if the morphological characteristics of 
the lesion prevent it from being picked up on CT. The converse may also be true, where a 
larger less active, or non-avid lesion, may be overlooked. Well differentiated thyroid 
carcinomas tend to have lower FDG avidity while lung carcinoids are typically considered 
non-avid.29 Hybrid imaging improves the detection of non-FDG avid tumours and lesions but 
questions remain about how much time should be invested assessing AC images for non-
avid abnormalities. 
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An additional point of interest concerns our secondary analysis of data to investigate the 
impact of tube charge and slice thickness. This analysis highlights the statistical power 
advantage of a location based analysis in observer studies. The wJAFROC FOM was still 
able to detect a statistical difference in nodule detection performance when the smallest 
nodules (5 mm) were removed, while the HR ROC analysis was not sensitive to the 
difference in performance. This is an important point to consider when planning an observer 
study that involves precise localisation. We also applied the maxLLF FOM to indicate lesion 
level detection (sensitivity); this again showed a highly significant difference in performance 
in favour of DQ. 
There are some limitations to our work. Phantom studies are useful when comparing 
imaging methods under controlled conditions, removing the influence of case variation. 
However, the relevance to clinical interpretations can be limited and of this type of result 
should be carefully considered. Additionally, this phantom did not account for respiratory 
motion. Continuous breathing techniques have been employed in PET/CT examinations but 
there is a growing acceptance of breath-hold CT scanning30–32 for pulmonary pathology, 
which is better represented by the phantom model in this research than a simulation of 
respiratory motion. However, respiratory motion is an important consideration, but currently 
we do not know the impact of respiratory motion on nodule detection in this phantom. A 
study that emulates respiratory motion in this phantom is underway. 
Additionally, we do not know the impact of ATCM on nodule detection. ATCM is widely 
accepted as a suitable dose reduction method for DQ imaging33–37 but despite the mA being 
limited to operate within upper and lower limits,35 previous work19 suggests the selection of 
“noise index” can be arbitrary and radiation dose may not be adequately optimised. Future 
work could assess nodule detection in DQ images acquired with and without ATCM using 
observer performance studies patterned on the current work. 
Conclusion 
Nodule detection was significantly worse on images acquired for AC as compared to DQ and 
it suggests that images for AC should not be used for interpretation of non-avid lesions. 
Even when the smallest nodules (5 mm) were removed from the analysis, a statistically 
significant difference remained for the specification of nodules used in this study. 
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